Moreover, it has been shown that patients with EGFR mutations have fewer T cell infiltrations of PD-L1+/CD8+ tumor infiltrating lymphocytes (TILs) and reduced shrinking properties of the tumor in response to immune cell activation (Figure 2C, Dong et al., 2017a). This evidence concerns the gene CD274 and neoplasm.